SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 181-194

  Bologna, Cinzia ^a,b   Buonincontri, Roberta ^a,b   Serra, Sara ^b   Vaisitti, Tiziana ^a,b   Audrito, Valentina ^b   Brusa, Davide ^a,b   Pagnani, Andrea ^b,c   Coscia, Marta ^d   D'Arena, Giovanni ^e   Mereu, Elisabetta ^f   Piva, Roberto ^f   Furman, Richard R ^g   Rossi, Davide ^h   Gaidano, Gianluca ^h   Terhorst, Cox ⁱ   Deaglio, Silvia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Human Genetics Foundation   (Italy)

^c POLITECNICO DI TORINO   (Italy)

^d CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^e REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF EASTERN PIEDMONT   (Italy)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; CD150 ANTIGEN; CD38 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FLUDARABINE; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE 1; SYNAPTOPHYSIN; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; REACTIVE OXYGEN METABOLITE; SLAMF1 PROTEIN, HUMAN;

ARTICLE; AUTOPHAGY; CANCER SURVIVAL; CELL MIGRATION; CHEMOTAXIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; OVERALL SURVIVAL; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; CELL MOTION; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, CD; AUTOPHAGY; CELL MOVEMENT; CHEMOTAXIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MAP KINASE KINASE 4; REACTIVE OXYGEN SPECIES; RECEPTORS, CELL SURFACE; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE FAMILY MEMBER 1;

EID: 84956643600     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83013     Document Type: Article

References (66)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815.
2. Gaidano G, Foa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432-3438.
3. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592-601.
4. Dal Bo M, et al. Microenvironmental interactions in chronic lymphocytic leukemia: The master role of CD49d. Semin Hematol. 2014;51(3):168-176.
5. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: A decade later. Blood. 2011;118(13):3470-3478.
6. Dohner H, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
7. Mertens D, et al. Chronic lymphocytic leukemia and 13q14: miRs and more. Leuk Lymphoma. 2009;50(3):502-505.
8. Cimmino A, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944-13949.
9. Ng SY, Davids MS. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2014;12(4):224-229.
10. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007;8(11):931-937.
11. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27-42.
12. Strohecker AM, White E. Targeting mitochondrial metabolism by inhibiting autophagy in BRAFdriven cancers. Cancer Discov. 2014;4(7):766-772.
13. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571-580.
14. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401-410.
15. Galluzzi L, et al. Autophagy in malignant transformation and cancer progression. EMBO J. 2015;34(7):856-880.
16. Huang JJ, Zhu YJ, Lin TY, Jiang WQ, Huang HQ, Li ZM. Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Hum Pathol. 2011;42(10):1459-1466.
17. Calpe S, et al. The SLAM and SAP gene families control innate and adaptive immune responses. Adv Immunol. 2008;97:177-250.
18. Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol. 2006;6(1):56-66.
19. Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol. 2003;3(10):813-821.
20. Berger SB, et al. SLAM is a microbial sensor that regulates bacterial phagosome functions in macrophages. Nat Immunol. 2010;11(10):920-927.
21. Seifert M, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183-2198.
22. Mittal AK, et al. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. Int J Mol Med. 2007;20(4):461-469.
23. Zucchetto A, et al. Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia. Immunol Lett. 2011;134(2):137-144.
24. Schweighofer CD, et al. A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia. PLoS One. 2011;6(12):e28277.
25. Isomaki P, et al. Increased expression of signaling lymphocytic activation molecule in patients with rheumatoid arthritis and its role in the regulation of cytokine production in rheumatoid synovium. J Immunol. 1997;159(6):2986-2993.
26. Deaglio S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood. 2007;110(12):4012-4021.
27. Vaisitti T, et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia. 2010;24(5):958-969.
28. Buggins AG, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol. 2011;154(2):216-222.
29. Deaglio S, Vaisitti T, Zucchetto A, Gattei V, Malavasi F. CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Semin Cancer Biol. 2010;20(6):416-423.
30. Ocana E, et al. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica. 2007;92(3):349-356.
31. Zucchetto A, et al. A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. J Cell Physiol. 2006;207(2):354-363.
32. Wang RC, et al. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. Science. 2012;338(6109):956-959.
33. Funderburk SF, Wang QJ, Yue Z. The Beclin 1-VPS34 complex - at the crossroads of autophagy and beyond. Trends Cell Biol. 2010;20(6):355-362.
34. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140(3):313-326.
35. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3(6):542-545.
36. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol. 2007;17(9):422-427.
37. Liu P, et al. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia. 2012;26(6):1293-1300.
38. Wang G, et al. Migration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8. PLoS One. 2015;10(3):e0121968.
39. Ogata M, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol. 2006;26(24):9220-9231.
40. Corcelle E, et al. Control of the autophagy maturation step by the MAPK ERK and p38: lessons from environmental carcinogens. Autophagy. 2007;3(1):57-59.
41. Matsunaga K, et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol. 2009;11(4):385-396.
42. Zhong Y, et al. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol. 2009;11(4):468-476.
43. Pattingre S, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122(6):927-939.
44. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J. 2008;410(1):1-17.
45. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 2008;30(6):678-688.
46. Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy. 2008;4(7):949-951.
47. Pietrocola F, et al. Regulation of autophagy by stress-responsive transcription factors. Semin Cancer Biol. 2013;23(5):310-322.
48. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40(2):280-293.
49. Ricci F, Tedeschi A, Morra E, Montillo M. Fludarabine in the treatment of chronic lymphocytic leukemia: A review. Ther Clin Risk Manag. 2009;5(1):187-207.
50. Pedro JM, et al. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy. Autophagy. 2015;11(3):452-459.
51. Notte A, Leclere L, Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol. 2011;82(5):427-434.
52. Ekiz HA, Can G, Baran Y. Role of autophagy in the progression and suppression of leukemias. Crit Rev Oncol Hematol. 2012;81(3):275-285.
53. Nencioni A, et al. Autophagy in blood cancers: biological role and therapeutic implications. Haematologica. 2013;98(9):1335-1343.
54. Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 2012;120(6):1262-1273.
55. MacCallum SF, et al. Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep. 2013;3:1275.
56. Mahoney E, Byrd JC, Johnson AJ. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclindependent kinase inhibitor flavopiridol. Autophagy. 2013;9(3):434-435.
57. Vaisitti T, et al. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia. 2015;29(2):356-368.
58. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033-3046.
59. Nowakowski GS, et al. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol. 2009;27(11):1844-1849.
60. Ghavami S, et al. Autophagy is a regulator of TGF-β1-induced fibrogenesis in primary human atrial myofibroblasts. Cell Death Dis. 2015;6:e1696.
61. Valdor R, et al. Chaperone-mediated autophagy regulates T cell responses through targeted degradation of negative regulators of T cell activation. Nat Immunol. 2014;15(11):1046-1054.
62. Pua HH, Dzhagalov I, Chuck M, Mizushima N, He YW. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J Exp Med. 2007;204(1):25-31.
63. Hubbard VM, Valdor R, Patel B, Singh R, Cuervo AM, Macian F. Macroautophagy regulates energy metabolism during effector T cell activation. J Immunol. 2010;185(12):7349-7357.
64. Oltersdorf T, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677-681.
65. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112-121.
66. Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol. 1963;17:208-212.